SAB Biotherapeutics is hoping to continue work on its COVID-19 antibody treatment after the National Institutes of Health (NIH) shut down a funded phase 3 clinical trial when the omicron wave slowed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results